FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
147 letters match. Newest first.
-
DrugsBiopreventative Company LLC dba Biopreventative
FDA told Biopreventative its website claim that compounded tadalafil is "commonly known as Cialis" misbrands the drug.
Low -
DrugsSprout Health Partners LLC dba Sprout Health
FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.
Low -
DrugsMaster Pharmaceuticals Group
FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.
High risk -
DrugsTRYM Health, Inc. dba TRYM Health
FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
Medium -
DrugsHealBerry
FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.
Medium -
DrugsReset IV, LLC dba Reset IV
FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.
Medium -
Drugsinspire.clinic
FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.
Low -
DrugsBioverse, Inc. dba Bioverse
FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.
Low -
DrugsSimpleRx
FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.
High risk -
DrugsElevate Your Wellness LLC, dba Elevated
FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.
Low -
DrugsCosmo Medical Spa dba Cosmo Med Spa
FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.
Medium -
DrugsEvoLife Wellness
FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.
Medium -
DrugseDrugstore
FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).
High risk -
DrugsNuvo Life Health Inc. dba Nuvo Life Health
FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.
Medium -
DrugsSemaBio
FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.
Low -
Drugsdirectmeds.com, Inc. dba DirectMeds
FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.
High risk -
DrugsHims & Hers Health, Inc. dba Hims
FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsMane & Steel, LLC. dba Mane & Steel
FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.
Low -
DrugsLumimeds
FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsASN-LABS
ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
High risk -
DrugsBody Good Studio
FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.
High risk -
DrugsCanada Med Stop
Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.
Medium -
DrugsAll American Wellness
FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.
Low -
DrugsHealthy Male
FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.
Low -
DrugsIntimate Rose
FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.
High risk -
DrugsInvigorate Med Spa
Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.
Low -
DrugsDr. Gater’s Weight Loss & Wellness
Dr. Gater’s Weight Loss & Wellness marketed compounded semaglutide and tirzepatide with false or misleading FDA-approval and generic-Ozempic claims.
Medium -
DrugsRemedy Meds
FDA warns Remedy Meds that its telehealth site misleadingly labels pharmacy-made semaglutide and tirzepatide with approved-drug comparisons.
Low -
DrugsEA WORKS Limited Liability Company dba Trust Labs
FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
High risk -
DrugsFancy Meds, LLC dba Fancy Meds
FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.
Low -
DrugsMatthew Stern, CEO MyStart Health LLC.
FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.
Low -
DrugsElite Health Center
FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.
Low -
DrugsCurex
FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.
High risk -
DrugsHealthon Inc. dba Healthon
FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.
Low -
Drugswww.peacefulmeds.com
FDA warned www.peacefulmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and injectable semaglutide to U.S. consumers online.
High risk -
DrugsPrime Vitality, Inc. dba Prime Peptides
FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.
High risk -
DrugsNomida.biz
FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.
High risk -
Drugswww.semaspace.com
FDA warned semaspace.com for selling unapproved, misbranded injectable semaglutide drugs online without prescriptions.
High risk -
Drugswww.gorillahealing.com
FDA warned gorillahealing.com for selling unapproved, misbranded semaglutide and tirzepatide drugs to U.S. consumers online.
High risk -
Drugscitypharma.us
FDA warned citypharma.us for selling unapproved, misbranded opioid, benzodiazepine, and stimulant drugs to U.S. consumers online.
High risk -
Drugsyourtramadol.com
FDA warned yourtramadol.com for selling unapproved and misbranded tramadol opioid products to U.S. consumers online.
High risk -
Drugskubapharm.com
FDA and DEA warned kubapharm.com it unlawfully sells high-abuse-risk stimulants, including Adderall, online without required registrations or prescriptions.
High risk -
Drugspremiumlightsupplier.com
FDA and DEA warned premiumlightsupplier.com that it unlawfully sells Schedule II stimulants, including Adderall, online without prescriptions or DEA registration.
High risk -
DrugsExtrapharmacy.ru
FDA warned Extrapharmacy.ru for selling unapproved, mislabeled prescription drugs, including COVID-19 treatments, to U.S. consumers online.
High risk